Literature DB >> 27986385

Natural History of the Central Structural Abnormalities in Choroideremia: A Prospective Cross-Sectional Study.

Tomas S Aleman1, Grace Han2, Leona W Serrano2, Nicole M Fuerst2, Emily S Charlson2, Denise J Pearson2, Daniel C Chung2, Anastasia Traband2, Wei Pan2, Gui-Shuang Ying2, Jean Bennett2, Albert M Maguire2, Jessica I W Morgan2.   

Abstract

PURPOSE: To describe in detail the central retinal structure of a large group of patients with choroideremia (CHM).
DESIGN: A prospective, cross-sectional, descriptive study. PARTICIPANTS: Patients (n = 97, age 6-71 years) with CHM and subjects with normal vision (n = 44; ages 10-50 years) were included.
METHODS: Subjects were examined with spectral-domain optical coherence tomography (SD OCT) and near-infrared reflectance imaging. Visual acuity (VA) was measured during their encounter or obtained from recent ophthalmic examinations. Visual thresholds were measured in a subset of patients (n = 24) with automated static perimetry within the central regions (±15°) examined with SD OCT. MAIN OUTCOME MEASURES: Visual acuity and visual thresholds; total nuclear layer, inner nuclear layer (INL), and outer nuclear layer (ONL) thicknesses; and horizontal extent of the ONL and the photoreceptor outer segment (POS) interdigitation zone (IZ).
RESULTS: Earliest abnormalities in regions with normally appearing retinal pigment epithelium (RPE) were the loss of the POS and ellipsoid zone associated with rod dysfunction. Transition zones (TZs) from relatively preserved retina to severe ONL thinning and inner retinal thickening moved centripetally with age. Most patients (88%) retained VAs better than 20/40 until their fifth decade of life. The VA decline coincided with migration of the TZ near the foveal center. There were outer retinal tubulations in degenerated, nonatrophic retina in the majority (69%) of patients. In general, RPE abnormalities paralleled photoreceptor degeneration, although there were regions with detectable but abnormally thin ONL co-localizing with severe RPE depigmentation and choroidal thinning.
CONCLUSIONS: Abnormalities of the POS and rod dysfunction are the earliest central abnormalities observed in CHM. Foveal function is relatively preserved until the fifth decade of life. Migration of the TZs to the foveal center with foveal thinning and structural disorganization heralded central VA loss. The relationships established may help outline the eligibility criteria and outcome measures for clinical trials for CHM.
Copyright © 2016 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 27986385      PMCID: PMC5319901          DOI: 10.1016/j.ophtha.2016.10.022

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  84 in total

1.  Choroid eremia.

Authors:  J K PAMEYER; P J WAARDENBURG; H E HENKES
Journal:  Br J Ophthalmol       Date:  1960-12       Impact factor: 4.638

2.  Choroideremia Is a Systemic Disease With Lymphocyte Crystals and Plasma Lipid and RBC Membrane Abnormalities.

Authors:  Alice Yang Zhang; Naveen Mysore; Hojatollah Vali; Jamie Koenekoop; Sang Ni Cao; Shen Li; Huanan Ren; Vafa Keser; Irma Lopez-Solache; Sorath Noorani Siddiqui; Ayesha Khan; Jeannie Mui; Kelly Sears; Jim Dixon; Jeremy Schwartzentruber; Jacek Majewski; Nancy Braverman; Robert K Koenekoop
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-12       Impact factor: 4.799

Review 3.  Optogenetics.

Authors:  Jens Duebel; Katia Marazova; José-Alain Sahel
Journal:  Curr Opin Ophthalmol       Date:  2015-05       Impact factor: 3.761

4.  High-resolution adaptive optics retinal imaging of cellular structure in choroideremia.

Authors:  Jessica I W Morgan; Grace Han; Eva Klinman; William M Maguire; Daniel C Chung; Albert M Maguire; Jean Bennett
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-09-04       Impact factor: 4.799

5.  Choroideremia. Study of a family and literature review.

Authors:  M L Rubin; R S Fishman; R A McKay
Journal:  Arch Ophthalmol       Date:  1966-10

6.  Macular pigment and lutein supplementation in choroideremia.

Authors:  Jacque L Duncan; Tomas S Aleman; Leigh M Gardner; Elaine De Castro; Daniel A Marks; Jessica M Emmons; Michelle L Bieber; Janet D Steinberg; Jean Bennett; Edwin M Stone; Ian M MacDonald; Artur V Cideciyan; Maureen G Maguire; Samuel G Jacobson
Journal:  Exp Eye Res       Date:  2002-03       Impact factor: 3.467

7.  Macular hole surgery in patients with end-stage choroideremia.

Authors:  Martin S Zinkernagel; Markus Groppe; Robert E MacLaren
Journal:  Ophthalmology       Date:  2013-04-04       Impact factor: 12.079

8.  Intraocular light scatter in patients with choroideremia.

Authors:  S Grover; K R Alexander; D M Choi; G A Fishman
Journal:  Ophthalmology       Date:  1998-09       Impact factor: 12.079

9.  Visual Acuity after Retinal Gene Therapy for Choroideremia.

Authors:  Thomas L Edwards; Jasleen K Jolly; Markus Groppe; Alun R Barnard; Charles L Cottriall; Tanya Tolmachova; Graeme C Black; Andrew R Webster; Andrew J Lotery; Graham E Holder; Kanmin Xue; Susan M Downes; Matthew P Simunovic; Miguel C Seabra; Robert E MacLaren
Journal:  N Engl J Med       Date:  2016-04-27       Impact factor: 91.245

10.  Retinal gene therapy in patients with choroideremia: initial findings from a phase 1/2 clinical trial.

Authors:  Robert E MacLaren; Markus Groppe; Alun R Barnard; Charles L Cottriall; Tanya Tolmachova; Len Seymour; K Reed Clark; Matthew J During; Frans P M Cremers; Graeme C M Black; Andrew J Lotery; Susan M Downes; Andrew R Webster; Miguel C Seabra
Journal:  Lancet       Date:  2014-01-16       Impact factor: 79.321

View more
  41 in total

1.  Visual Function at the Atrophic Border in Choroideremia Assessed with Adaptive Optics Microperimetry.

Authors:  William S Tuten; Grace K Vergilio; Gloria J Young; Jean Bennett; Albert M Maguire; Tomas S Aleman; David H Brainard; Jessica I W Morgan
Journal:  Ophthalmol Retina       Date:  2019-05-08

2.  Retinal dystrophy and subretinal drusenoid deposits in female choroideremia carriers.

Authors:  Vittoria Murro; Dario Pasquale Mucciolo; Ilaria Passerini; Simona Palchetti; Andrea Sodi; Gianni Virgili; Stanislao Rizzo
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-07-27       Impact factor: 3.117

3.  Long-term Natural History of Atrophy in Eyes with Choroideremia-A Systematic Review and Meta-analysis of Individual-Level Data.

Authors:  Liangbo L Shen; Aneesha Ahluwalia; Mengyuan Sun; Benjamin K Young; Holly K Grossetta Nardini; Lucian V Del Priore
Journal:  Ophthalmol Retina       Date:  2020-03-14

4.  CHOROIDEREMIA: Retinal Degeneration With an Unmet Need.

Authors:  Mark E Pennesi; David G Birch; Jacque L Duncan; Jean Bennett; Aniz Girach
Journal:  Retina       Date:  2019-11       Impact factor: 4.256

5.  FREQUENT SUBCLINICAL MACULAR CHANGES IN COMBINED BRAF/MEK INHIBITION WITH HIGH-DOSE HYDROXYCHLOROQUINE AS TREATMENT FOR ADVANCED METASTATIC BRAF MUTANT MELANOMA: Preliminary Results From a Phase I/II Clinical Treatment Trial.

Authors:  Akosua A Nti; Leona W Serrano; Harpal S Sandhu; Katherine E Uyhazi; Ilaina D Edelstein; Elaine J Zhou; Scott Bowman; Delu Song; Tara C Gangadhar; Lynn M Schuchter; Sheryl Mitnick; Alexander Huang; Charles W Nichols; Ravi K Amaravadi; Benjamin J Kim; Tomas S Aleman
Journal:  Retina       Date:  2019-03       Impact factor: 4.256

6.  Deep Scleral Exposure: A Degenerative Outcome of End-Stage Stargardt Disease.

Authors:  Winston Lee; Jana Zernant; Takayuki Nagasaki; Stephen H Tsang; Rando Allikmets
Journal:  Am J Ophthalmol       Date:  2018-07-26       Impact factor: 5.258

7.  SCLERAL PITS IN CHOROIDEREMIA: Implications for Retinal Gene Therapy.

Authors:  Abdullah A Al-Qahtani; Shakoor Ba-Ali; Talal Alabduljalil; Aaron S Coyner; Rachel C Patel; Richard G Weleber; Aniz Girach; Søren K Christensen; Michael Larsen; Mark E Pennesi; Paul Yang
Journal:  Retina       Date:  2018-09       Impact factor: 4.256

8.  Optical coherence tomography (OCT) features of cystoid spaces in choroideremia (CHM).

Authors:  Vittoria Murro; Dario Pasquale Mucciolo; Dario Giorgio; Andrea Sodi; Ilaria Passerini; Giacomo Bacci; Sara Bargiacchi; Gianni Virgili; Stanislao Rizzo
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-10-26       Impact factor: 3.117

9.  Ocular gene therapy for choroideremia: clinical trials and future perspectives.

Authors:  Kanmin Xue; Robert E MacLaren
Journal:  Expert Rev Ophthalmol       Date:  2018-05-18

Review 10.  Progress in treating inherited retinal diseases: Early subretinal gene therapy clinical trials and candidates for future initiatives.

Authors:  Alexandra V Garafalo; Artur V Cideciyan; Elise Héon; Rebecca Sheplock; Alexander Pearson; Caberry WeiYang Yu; Alexander Sumaroka; Gustavo D Aguirre; Samuel G Jacobson
Journal:  Prog Retin Eye Res       Date:  2019-12-30       Impact factor: 21.198

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.